Apr 22, 2020
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Apr 17, 2020
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma | US & EU Market Sizes from 2017 to 2030, Details of Marketed & Emerging Therapies Kymriah (Novartis) & KTE-X19 (Gilead Sciences)
Apr 13, 2020
Gracell to Present the First-in-human, Universal TruUCAR(TM) GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Annual Meeting
Apr 07, 2020
GenScript ProBio and Eutilex Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for CAR-T Programs
Apr 03, 2020
Gracell Announces China MNPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Mar 24, 2020
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T(TM)) Therapies
Mar 23, 2020
First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models
Mar 17, 2020
GEMoaB Announces Publication of Pre-Clinical Proof-of-Concept Data on UniCAR-modified Off-the-shelf Natural Killer Cells in 'Nature Scientific Reports'
Mar 10, 2020
PhRMA Report Shows Nearly 400 Cell and Gene Therapies in Development to Target a Broad Range of Diseases
Mar 09, 2020
GEMoaB Announces First Patient Apheresed in a Phase IA Study With Lead Product Candidate From Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias
Mar 02, 2020
Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million
Feb 27, 2020
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma
Feb 19, 2020
New study finds cellular immunotherapy treatment associated with improved quality of life
Feb 12, 2020
Anixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T Program
Feb 11, 2020
Marker Therapeutics Announces Update to its Clinical Program in AML
Feb 05, 2020
CytoSorb Used Successfully to Help Treat Grade 4 Cytokine Release Syndrome Following CAR T-cell Immunotherapy in First Published Case Report
Jan 28, 2020
2019 CAR-T Cell Therapy Market Study: Current Status, Patent Landscape, Funding, Deals, Research, Applications, Technologies, Marketed Products, Ongoing & Late Stage Clinical Trials
Jan 15, 2020
INTELLiSTEM Announces the Launch of a New Antigen Identification Platform for the Development of Novel Car T Cells
Jan 14, 2020
John Theurer Cancer Center Investigators Report Transformative Results of CAR T-Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Jan 08, 2020
Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy